Pharma Marketletter articles from August 2004

Pharma Marketletter archives from August 2004

AstraZeneca's 2nd-qtr sales jump 19%.(financial reports)
August 2, 2004... UK-based AstraZeneca has followed its European rivals Novartis, Roche and Schering AG in posting results ahead of expectations for the second quarter of 2004. The company posted a 24% leap in operating profit to $1.1 billion (on a reported...

Daily vitamin pill may slow AIDS progress.(Brief Article)
August 2, 2004... Research published in the New England Journal of Medicine suggests that multivitamin supplements may delay the progression of HIV disease and provide an effective, low-cost way of delaying the start of antiretroviral therapy in HIV-infected...

Positive new data for Sabinsa's ForsLean.(Brief Article)
August 2, 2004... Herbal extracts manufacturer and supplier Sabinsa has reported promising new safety and efficacy data for its weight management product ForsLean (Coleus forskohlii extract). The 12-week, double-blind and randomized trial involved 60 obese...

Omega-3s protect against prostate cancer.(Brief Article)
August 2, 2004... A new study published in the July issue of the American Journal of clinical Nutrition suggests that men with higher intakes of the omega-3 fatty acids, eicosapentaenoic acid and docosahexaenoic acid, could be at lower risk of developing...

Micap's product to be tested for MRSA in UK.(Manchester Local Research Ethics Committee)(Brief Article)
August 2, 2004... Micap says it has received clearance from the Manchester Local Research Ethics Committee, UK, to begin a Phase I trial of its Micap encapsulated biocide and essential oil product for the control of methicillin-resistant Staphylococcus aureus....

Serono's 2nd-qtr net income jumps 26%.(financial results)
August 2, 2004... Swiss biotechnology giant Serono turned in a robust performance for the second quarter of 2004, achieving a 26% increase in net income to $135.8 million, on strong sales of the firm's multiple sclerosis drug Rebif (interferon beta-1a). Basic...

Schering AG raises 2004 forecast on 2nd-qtr.
August 2, 2004... German drugmaker Schering AG saw its operating profit climb 10% to 413 million euros ($514 million) for the first half of 2004, leading to a 4% increase in net profit of 259 million euros for the period, falling above general expectations....

FDA OKs Seroquel labeling changes for BD.(AstraZeneca's Bipolar disorder)(Food and Drug Administration)
August 2, 2004... Anglo-Swedish drug major AstraZeneca says that the US Food and Drug Administration has approved additional efficacy labeling information based on 12-week data for Seroquel (quetiapine) in patients with bipolar I disorder. This makes it the...

Agensys signs accord with Genentech.(contracts)(Brief Article)
August 2, 2004... Agensys, a privately-held US firm, has entered into an agreement with biotechnology giant Genentech for the research, development and commercialization of therapeutic and diagnostic products to two of the former's proprietary cancer targets....

Jerini's icatibant on FDA fast-track.(Food and Drug Administration)(Brief Article)
August 2, 2004... The US Food and Drug Administration has awarded fast-track designation to German drugmaker Jerini's icatibant as a subcutaneous treatment for hereditary angioedema. The agent is a bradykinin B2 receptor antagonist, and is currently...

AstraZeneca urges FDA on Crestor petition.(Food and Drug Administration)
August 2, 2004... AstraZeneca, Europe's second-largest drugmaker, has presented a comprehensive, 30-page response to the US Food and Drug Administration urging the agency to remove Public Citizen's Health Research Group's petition to ban its cholesterol-lowering...

EU "pharming" project for major-disease R&D.
August 2, 2004... A team of European researchers plans to perfect techniques for producing antibodies and vaccines obtained from plants to prevent and treat major human diseases such as HIV/AIDS, rabies and tuberculosis. Pharma-Planta is a consortium of...

Germany: same price for generic, brand statins?(Brief Article)
August 2, 2004... As part of the plan to include cholesterol-lowerers in Germany's fixed-level drug price support system, a government- appointed panel of doctors and health insurers has proposed that both brand-name and generic drugs be included in the same...

Bulgarian Rx sales to Iraq.(Brief Article)
August 2, 2004... Bulgarian drugmakers are recording healthy sales in Iraq, reports the Bulgarian Economic Review. The companies export their medicines to Jordan and Turkey, where they are picked up by Iraqi partners. However, the firms' plans to construct a...

Austria faces need for health reforms.
August 2, 2004... The Austrian health care service is facing a costs crisis. Spending on health has risen 1% a year faster than growth in Gross Domestic Product and there has been no sign of a change in this trend. This is seen by government economists as...

Dutch EU presidency outlines priorities.
August 2, 2004... The Dutch presidency of the Council of the European Union has outlined its priorities and agenda for 2004, which include aspects of health care, in a 34-page document released last week. On pharmaceuticals, it notes that the EU strategy and...

Fen-Phen Trust solution approved.(reduced settlements to fen-phen victims)(Brief Article)
August 2, 2004... US attorneys who represent victims of the fen-phem weightloss products say that their negotiations to create an amendment to the Fen-Phen Trust have been tentatively approved by both sides. The proposed agreement - labeled the 7th Amendment -...

Boston and Angiotech get FDA OK for paclitaxel stent trial.(Food and Drug Administration )(Brief Article)
August 2, 2004... Angiotech and its partner Boston Scientific say they have received an Investigational Device Exemption from the US Food and Drug Administration to begin its ATLAS clinical trial. ATLAS is the first clinical trial using Boston's new Liberte...

Viragen to produce Multiferon at new Swedish facility.(Brief Article)
August 2, 2004... USA-based Viragen has said that its Swedish manufacturing facility in Ersboda is on schedule to commence with the production of Multiferon (interferon alpha) in September. The company has been upgrading and expanding its production capabilities...

Spectrum seeks Berlin exchange de-listing.(Spectrum Pharmaceuticals)(Brief Article)
August 2, 2004... Spectrum Pharmaceuticals of the USA says that it has sent a formal demand letter to the Berlin Stock Exchange requesting that the company's common stock and any other of its securities be de-listed. Spectrum did not ever apply for a...

Boston to buy drugs from Canada.(Brief Article)
August 2, 2004... Boston is to become the largest city in the USA so far to purchase prescription drugs supplied through its employee and retiree health plans from Canada, in a move which it expects to save around $1 million in its first year. When the...

US FDA standard format for human clin trial data.(Food and Drug Administration )(Brief Article)
August 2, 2004... The US Food and Drug Administration has announced a standard format for the submission of data by sponsors of human drug clinical trials. Use of the Study Data Tabulation Model, developed by the Clinical Data Interchange Standards Consortium,...

US consumers "unaware of fake drugs".(Brief Article)
August 2, 2004... While US consumers are often turning to the Internet for their prescription drug needs, most do not know how to tell whether the drugs sold are legitimate, an on-line poll conducted by the US National Consumers League has found. Over half...

Florida subpoenas six generics makers.(Brief Article)
August 2, 2004... The Attorney General of the US state of Florida has subpoenaed six generic drugmakers, on suspicion that their wholesale pricing practices have resulted in the state Medicaid program being overcharged more than $100 million from 1994 to now....

Indian drug price study sees large trade margins.(Brief Article)
August 2, 2004... An Indian government study of the prices being charged in Delhi for three widely-used prescription drugs has found very wide variations within the prices charged for branded and generic versions of the same drug. The study, which was...

Indian 2004-5 budget disappoints pharma.(Brief Article)
August 2, 2004... India's federal 2004-5 budget has disappointed the local pharmaceutical industry as it provides no tax incentives for R&D and makes no mention of the company's transition into a product patent regime from early next year. "This budget has...

S Africa panel to hear complaint against GSK.(GlaxoSmithKline)(Brief Article)
August 2, 2004... South Africa's Competition Commission has agreed to hear a complaint filed by individual South African citizens and the AIDS Healthcare Foundation against GlaxoSmithKline which, the plaintiffs allege, has priced its HIV/ AIDS drugs excessively,...

Indian govt warns over drug marketing curbs.(Brief Article)
August 2, 2004... Attempts to ban the sale of medicines which are not included in the national pharmacopoeia would be a retrograde step, India's Ministry of Health and Family Welfare has said. In testimony before India's Supreme Court, which is considering...

China backs UK, Germany for pharma investment.(Brief Article)
August 2, 2004... China's Ministries of Commerce and of Foreign Affairs have published a guidance list recommending the best countries in which to invest for particular industries. The report recommends the UK for investing in the biopharmaceutical industry...

Israeli drug prices.
August 2, 2004... The consumer price of pharmaceuticals in Israel in June was up 0.8% on May and 0.8% higher than in June 2003, reports the Central Bureau of Statistics. This compares with an unchanged consumer price index for both periods.

AstraZeneca's Seroquel effective in treating agitation in elderly with dementia.
August 2, 2004... At the 9th International Conference on Alzheimer's Disease and Related Disorders, held in Philadelphia, USA, new data were presented which reveal that elderly patients with dementia, including those with Alzheimer's disease, who are treated...

Merck & Co/S-P's Vytorin OKed by FDA.(Food and Drug Administration)(Brief Article)
August 2, 2004... Merck & Co and Schering-Plough's dual-action cholesterol-lowerer Vytorin (ezetimibe/simvastatin) has been approved by the US Food and Drug Administration for the treatment of low-density lipoprotein cholesterol in patients with primary...

Elan/Biogen's NDA for Antegren accepted.(licensing from Food and Drug Administration)(Brief Article)
August 2, 2004... USA-based Biogen Idec and Ireland's Elan Corp say that their Biologics License Application for Antegren (natalizumab) as a treatment for multiple sclerosis has been accepted by the US Food and Drug Administration. Recently, the agency...

Phytopharm's Myogane gets Orphan Drug status.(from Food and Drug Administration )(Brief Article)
August 2, 2004... The US Food and Drug Administration has awarded Orphan Drug designation to Phytopharm's Myogane (PYM50018) for the treatment of amyotrophic lateral sclerosis (also known as Lou Gehrig's disease). The UK firm recently reported the successful...

Mylan makes $4 billion agreed offer for King Pharma to lift branded sector.(Mylan Laboratories)(finance)
August 2, 2004... US generic drugmaker, Mylan Laboratories, says it has signed a definitive agreement to acquire King Pharmaceuticals in a stock-for-stock transaction. Under the terms of the deal, which the boards of both companies have approved, King...

Bayer to sell plasma unit for $600M+?(finance)(Brief Article)
August 2, 2004... If press speculation is correct, Germany's Bayer could gain in excess of $600 million from the sale of the blood plasma operations within its Biological Products division, which the firm has previously said it would divest (Marketletter March...

Australia's Amrad to spin-out Avexa.(Brief Article)
August 2, 2004... Australian biotechnology firm Amrad is planning, later this year, to spin-out its anti-infectives drug portfolio into a new company, Avexa, which will have a market capitalization of A$24 million ($17.6 million), of which the parent will...

Savient to re-focus; sell B-TG Israel?(Savient Pharmaceuticals)(Bio-Technology General )(Brief Article)
August 2, 2004... US firm Savient Pharmaceuticals has completed an evaluation of its assets and business strategy. Based on this, the board has approved management's recommendation to refine the company's strategic business plan to reposition itself to focus on...

Nicholas Piramal optimistic on exports.(forecasts)(Brief Article)
August 2, 2004... India's Nicholas Piramal says that, over the next three to four years, it expects exports to contribute around 50% to its current 13 billion-rupee ($282.1 million) annual turnover, up from just 9% in 2004, due to the company's focus on contract...

Novartis sales up in Australia and India.(financial results)(Brief Article)
August 2, 2004... Swiss drug major Novartis saw turnover in Australia rise nearly 11% to A$333.0 million ($243.8 million) on increasing demand for its human drug and animal health products in 2003, and the business turned in a net profit of A$6.6 million...

Baxter to restate results, revises 2004 forecast.(financial results of Baxter International)(Brief Article)
August 2, 2004... Baxter International plans to restate financial results for the years 2001-3 and the first quarter of 2004, as a result of incorrect revenue recognition and inadequate provisions for bad debts in Brazil, the company said. Consequently, the...

Celgene raises 2004 guidance on 2nd-qtr.(financial results)(Brief Article)
August 2, 2004... Celgene Corp turned in a solid performance for the second quarter of 2004, causing the US firm to raise its forecast for the full year. Total sales are expected to hit $370-$390 million compared to original guidance of $365-$385 million;...

Millennium's 2nd-qtr net loss drops 50%.(financial results of Millennium Pharmaceuticals)(Brief Article)
August 2, 2004... Millennium Pharmaceuticals of the USA saw its second-quarter 2004 net loss fall 50% to $53.9 million, or $0.18 per share. The narrower net loss for the quarter is due to higher sales of Velcade (bortezomib) injection for multiple myeloma and a...

QLT's revenues up 22% in 2nd-qtr 2004.(financial reports)(Brief Article)
August 2, 2004... Canada-based QLT Therapeutics saw its second-quarter 2004 sales climb 22% to $44 million, on a substantial increase in the use of the firm's key drug Visudyne (verteporfin) for the treatment of macular degeneration, a leading cause of blindness...

MedImmune's 2nd-qtr plunges into loss.(financial reports)(Brief Article)
August 2, 2004... In April this year, MedImmune terminated its vaccine technology development and marketing agreement with fellow US drugmaker Wyeth. The termination charges associated with this move helped to push earnings of $13 million posted for...

Chiron's 2nd-qtr income dips but sales rise.(financial results)(Brief Article)
August 2, 2004... Chiron's acquisition of PowderJect Pharmaceuticals last year (Marketletters passim) continued to bite into the US firm's earnings, with second-quarter pro forma net income falling 28% to $48 million, or $0.25 a share, from the year-ago period....

Major opportunities for life sciences in biodefense market.
August 2, 2004... Biodefense research is one of the fastest-growing markets for life science product suppliers, with US government spending in this area likely to continue growing faster than in other areas of biological R&D, says a new study from...

US Medicare Rx price cuts could close "doughnut" hole, but with costs to R&D: study.
August 2, 2004... If US Medicare were to match drug prices in Canada, France and the UK, where consumers in 2003 paid an average 34%- 59% of the costs to Americans of a similar market basket of pharmaceuticals, the "doughnut" hole (coverage gap) in the new...

Florida to end pharma disease programs.(Brief Article)
August 2, 2004... The US state of Florida will not renew in 2005 the disease management programs which it began three years ago with drugmakers in return for including the companies' products on its Medicaid formulary and which the firms had pledged would save...

Merck KGaA lifts 2004 forecast on strong qtr.(financial results)(Brief Article)
August 2, 2004... Germany's Merck KGaA has raised its guidance for full-year 2004, saying that profits should rise at least 150% as opposed to the originally-forecast high double-digit growth rate, driven by sales of key products, Liquid Crystals and Erbitux...

Actelion posts 1st-half sales growth of 63%.(financial reports)(Brief Article)
August 2, 2004... Switzerland-based Actelion has posted total net revenues of 215.0 million Swiss francs ($170.2 million) for the first half of 2004, marking a 63% increase from the 131.6 million francs recorded for the year-ago period. Sales were led by strong...

Schwarz' 1st-half 2004 sales tumble 49.9%.(Schwarz Pharma)(Brief Article)
August 2, 2004... German drugmaker Schwarz Pharma saw its sales for the first half of 2004 fall 49.9% to 490.4 million euros ($595.5 million), in line with expectations, as competition ate into the US market share of the company's generic omeprazole in addition...

New AD therapies designed to stop progression of disease not just symptoms.
August 2, 2004... At the 9th International Conference on Alzheimer's Disease and Related Disorders in Philadelphia, USA, a news briefing highlighted novel agents that may be able to stop the formation of beta-amyloid and thereby prevent progression of AD. ...

Antisoma gains rights to BC1-IL12.(Brief Article)
August 2, 2004... UK-based Antisoma, a biopharmaceutical firm specializing in the development of novel anticancer drugs, has gained exclusive rights to BC1-IL12. This follows the company's acquisition of EMD Lexigen's (an affiliate of Germany's Merck KGaA) half...

ISTA's NDA for Xibrom to be reviewed by FDA.(Brief Article)
August 2, 2004... ISTA Pharmaceuticals says that the US Food and Drug Administration has accepted for filing and review its New Drug Application for Xibrom (0.1% bromfenac sodium ophthalmic solution), a topical, twice-daily, non-steroidal anti-inflammatory...

FDA OK for liquid version of Synagis.(Brief Article)
August 2, 2004... US biotechnology firm MedImmune has received US Food and Drug Administration approval for a new liquid formulation of its anti-infective Synagis (palivizumab). In 1998, the original version of the monoclonal antibody was cleared by the FDA...

Australia Rx review plan published for comment.
August 2, 2004... The Australian government has now published the structure of the independent review mechanism for applications to list drugs on the Pharmaceutical Benefits Scheme (Marketletter July 26) to which it committed under the Australia/USA Free Trade...

Roche offer to New Zealand research.(Auckland Cancer Society Research Centre )(Brief Article)
August 2, 2004... Swiss drugmaker Roche has offered to partly fill a funding gap for the Auckland Cancer Society Research Centre in New Zealand, after Pfizer cancelled a NZ$66 million ($42 million) grant to the institution (Marketletter May 17). Roche has,...

GSK mulls S African HIV/AIDS Rx price suit.(GlaxoSmithKline)(Brief Article)
August 2, 2004... GlaxoSmithKline is considering whether to appeal the South African Competition Commission decision on July 23 that the Competition Tribunal should hear a complaint against its HIV/AIDS drug pricing policies brought by the USA-based AIDS...

GSK's 2nd-qtr 2004 EPS drops 12%.(GlaxoSmithKline)(financial results)(european pharma sales)
August 2, 2004... UK drugmaker GlaxoSmithKline is continuing its rough ride through 2004, having posted a 12% drop in second-quarter earnings to 20.1 pence a share (as per statutory results), on increasing generic competition and a weak US dollar, the firm said....

Editor's views on Vytorin approval; drug share price vagaries.(Editorial)
August 2, 2004... Letter from the Editor There was good news this week, albeit expected, for ailing Schering-Plough and partner Merck & Co, with the approval by the US Food and Drug Administration of their new, blockbuster-potential, dual-action...

Eyetech sees losses grow on Macugen development costs.(Eyetech Pharmaceuticals)(Brief Article)
August 2, 2004... Eyetech Pharmaceuticals, a US biopharmaceutical company that specializes in the development and commercialization of novel therapeutics to treat diseases of the eye, has reported consolidated financial results for the three months ended June...

FDA OK for Par Pharma's generic Mycostatin.(Food and Drug Administration )(Brief Article)
August 2, 2004... US firm Par Pharmaceutical says that its wholly-owned subsidiary, Kali Laboratories, has received final approval from the US Food and Drug Administration for its Abbreviated New Drug Application for nystatin topical powder (100,000 units/gram)....

Generx completes $3M financing.(Generex Biotechnology )(Brief Article)
August 2, 2004... Canada's Generex Biotechnology says that it has received an aggregate of C$3 million ($2.3 million) in equity financing through a private placement of common stock and warrants (including the C$1.75 million previously announced). Investors...

Another US firm OXiGENE, demands Berlin de-listing.(Berlin-Bremen Exchange)(Brief Article)
August 2, 2004... US biopharmaceutical firm OXiGENE says that it has sent a letter to Germany's Berlin-Bremen Exchange, demanding that the company be de-listed and that trading of its stock cease immediately. OXiGENE, like several companies before it, says it...

Cimex to list on Paris bourse.(securities)(Brief Article)
August 2, 2004... Swiss drug company Cimex Pharma will be listed on the Paris, France, stock exchange's second market, effective August 2, at a price that has been fixed at 8.30-8.70 euros per share.

Tokyo pharma stocks - week to july 26.
August 2, 2004... Tokyo saw an extended pullback in the week to July 26, influenced by a steep setback on New York markets. The Nikkei 225 fell 2.4%, to close at 11,159.55, the lowest level in seven weeks, while the Topix index declined 2.1%. Japanese investors...

Aventis posts flat 2nd-qtr 2004 earnings.(financial results)(Brief Article)
August 2, 2004... Franco-German drugmaker Aventis has posted net income of 610 million euros ($741 million) for the second quarter of 2004, climbing 1.2% over the comparable period of last year, but falling short of Lehman Brothers' forecast of 810 million...

Zeltia's first-half sales up 6.4%.(financial results)(Brief Article)
August 2, 2004... Spain's Zeltia has recorded sales of 42.8 million euros ($52.0 million) for the first half of 2004, marking a 6.4% rise on those posted for the year-earlier period. The company's subsidiaries, Zelnova and Xylazel, generated 94.3% of total group...

Genetix' profits up 45% for 1st-half.(financial results of Genetix Group)(Brief Article)
August 2, 2004... The UK's Genetix Group, a provider of molecular biology tools, has posted profit before tax (excluding goodwill) of L600,000 ($1.1 million), rising 45% on the like, year-earlier period. Adjusted earnings per share leapt 51% to 47 pence. ...

UK NICE "conquering the world, but....".(National Institute for Clinical Excellence)
August 2, 2004... Six years after it was introduced in the UK government's National Health Service Plan of 1998, the National Institute for Clinical Excellence, which makes recommendations on the treatments to be provided by the NHS in England and Wales, is...

Plavix with low-dose aspirin in ACS: NICE.(National Institute for Clinical Excellence)(acute coronary syndrome)(Brief Article)
August 2, 2004... Sanofi-Synthelabo/Bristol-Myers Squibb's Plavix (clopidogrel) should be used, together with low-dose aspirin, in people with non-ST-segment-elevation acute coronary syndrome who have a moderate to high risk of a major heart attack or death, the...

UK Ministers urge Brussels over generics.(Brief Article)
August 2, 2004... UK Ministers have urged the European Commission to issue, as a priority, a draft regulation to allow generic drugmakers to produce cheaper versions of drugs to treat health emergencies such as HIV/AIDS, tuberculosis and malaria in the world's...

Irish pharma trade with non-EU countries.(Brief Article)
August 2, 2004... Ireland imported medical and pharmaceutical products worth 343 million euros ($416.5 million) from non-European Union states in the first five months of 2004, compared to 366 million euros-worth in January-May 2003, reports the Central...

Pharma-Biotech alliances generating wave of new breast cancer therapeutics.
August 2, 2004... Strategic alliances between the pharmaceutical industry and the biotechnology sector are making breast cancer therapeutics one of the most dynamic segments in the overall oncology market. These partnerships are producing novel, targeted...

Sunesis in antiviral deal with Merck & Co.(Merck and Company Inc.)(Sunesis Pharmaceuticals Inc.)(Brief Article)
August 2, 2004... Sunesis Pharmaceuticals of the USA has entered into a multi-year research collaboration with US drug major Merck & Co to discover novel orally-available drugs for the treatment of viral infections. Under the terms of the accord, Sunesis...

Shionogi licenses Enanta's antibiotic.(Enanta Pharmaceuticals Inc.)(Shionogi and Company Ltd.)(Brief Article)
August 2, 2004... Enanta Pharmaceuticals of the USA and Japan's Shionogi have signed a deal to develop and commercialize the former's EP-013420, a first-in-class bridged bicyclic ketolide antibiotic, for the treatment of community respiratory tract infections,...

Strong 2nd-qtr sales sales for Cell Thera, but loss increases.(Cell Therapeutics Inc.)(Brief Article)
August 2, 2004... Cell Therapeutics of the USA says that revenues for the second quarter of 2004 were $8.3 million, up 36.1% on the like period of 2003, with net sales of Trisenox (arsenic trioxide) rising 49.1% to $7.9 million. The firm reported a net loss...

Approvable letter for Alza's Ionsys.(ALZA Corp.)(Brief Article)
August 2, 2004... Johnson & Johnson subsidiary Alza Corp says it has received an approvable letter from the US Food and Drug Administration regarding its New Drug Application for Ionsys, an iontophoretic gentanyl-containing transdermal analgesic. Alza adds...

Synarc competes IoDP acquisition.(IoDP Medical Imaging Research)(Brief Article)
August 2, 2004... Synarc, a USA-based provider of highly-specialized medical imaging and molecular marker services for global clinical trials, says that it has completed the acquisition of IoDP Medical Imaging Research, a provider of medical imaging services...

Pharmos net loss grows in 2nd qtr.(Pharmos Corp.)(Brief Article)
August 2, 2004... USA-based Pharmos Corp has reported second-quarter 2004 results showing that net loss was $5.3 million, or $.06 per share, compared to $4.3 million, or $.07 per share, in the like, 2003 period. The increase in net loss was due primarily to a...

XTLbio placement closed.(XTL Biopharmaceuticals Ltd.)(Brief Article)
August 2, 2004... Israel's XTL Biopharmaceuticals says that its open offer of over 56 million new ordinary shares, to raise proceeds of $17.8 million, closed on July 27. Valid applications in respect of around 12.3 million of these shares (21.9% of the...

AVANT demands Berlin stock exchange de-listing.(AVANT Immunotherapeutics Inc.)(Brief Article)
August 2, 2004... US firm AVANT Immunotherapeutics is the latest to demand an immediate de-listing from the Berlin-Bremen, Germany, Stock Exchange in an attempt to prevent trading practices that are banned in the USA. AVANT says it has recently learned that...

MedManage and Aptilon integrate on-line drug sampling and e-detailing.(MedManage Systems Inc.)(Aptilon Health)(Brief Article)
August 2, 2004... In the USA, MedManage Systems, a provider of on-line prescription drug-sampling solutions, says it has partnered with Aptilon Health, a leader in delivery of self-service and live e-marketing solutions for the health care industry. Through...